Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG-801 Phase 2 Trial in Hyperkalemia
NCT03799926Phase 2Completed
- Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Start
- Feb 2019
- Primary completion
- Nov 2019
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of patiromer in hyperkalemia (8 arms), sponsored by Zeria Pharmaceutical Co., Ltd. Primary endpoint: Change in serum potassium from baseline to 1 week after the start of administration. Started Feb 2019; status: completed.
02
Drugs
patiromer
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT03799926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03799926.